Refine
Has Fulltext
- yes (5)
Is part of the Bibliography
- yes (5)
Document Type
- Journal article (4)
- Doctoral Thesis (1)
Keywords
- small fiber neuropathy (2)
- Bruschit (1)
- Langerhans cells (1)
- ZNF365 (1)
- algorithm (1)
- common variants (1)
- consortium (1)
- corneal confocal microscopy (1)
- diagnosis (1)
- fibromyalgia (1)
- fibromyalgia syndrome (1)
- genetic variants (1)
- investigators (1)
- mesenchymale Stammzellen (1)
- modifiers (1)
- neurological examination (1)
- pain (1)
- population (1)
- selection (1)
- skin punch biopsy (1)
- subtypes (1)
- susceptibility alleles (1)
Institute
EU-Project number / Contract (GA) number
- 223175 (1)
Damit die Knochenregeneration lege artis abläuft ist ein sensibles und komplexes Zusammenspiel einer Reihe von Faktoren notwendig. Neben bestimmten Zelltypen, die für die Knochenregeneration essentiell sind, sind auch eine Reihe von Wachstumsfaktoren notwendig um die Kommunikation zwischen den Zellverbänden zu gewährleisten und die einzelnen Entwicklungsstadien zu steuern und zu regulieren.
Zur Untersuchung der Möglichkeit, sowohl die Osteokonduktion als auch Vaskularisation eines Scaffolds zu initiieren, wurden in der vorliegenden Arbeit verschiedene Untersuchungsmethoden eingesetzt. Damit wurden adulte humane mesenchymale Stammzellen untersucht, die zur Differenzierung mit den Wachstumsfaktoren bone morphogenetic protein 2 (BMP 2) und/oder vascular endothelial grwoth factor (VEGF) inkubiert und auf Glas- oder Bruschitoberflächen kultiviert wurden. Die Experimente wurden mittels immunologischer Methoden wie Immunfluoreszenz (IF) und Westernblot (WB), sowie über Rasterelektronenmikroskopie (REM) analysiert. Es konnte mit diesen Methoden gezeigt werden, dass die humanen mesenchymalen Stammzellen (hMSC) auf den verschiedenen Substraten adhärierten und proliferierten. Darüber hinaus konnte in der Arbeit nachgewiesen werden, dass unter diesen bestimmten Bedingungen sowohl knöcherne als auch vaskuläre Zellbildung angeregt werden kann. So konnte sowohl auf Glas als auch auf Bruschit mittels IF und REM zum Teil aus hMSC differenzierte Osteoblasten detektiert werden. Diese zeigten die für Osteoblasten typischen Zellfortsätze, mit denen die Osteoblasten mit den Nachbarzellen in Kontakt stehen. Die beginnende Differenzierung zu Osteoblasten bzw. Endothelzellen konnte auch durch Detektion spezfischer Marker, wie z.B. alkalische Phosphatase und PECAM mittels WB gezeigt werden. Jedoch war die in dieser Arbeit zur Untersuchung der ortsgerichteten Differenzierung auf Bruschitsubstrat eingesetzte Methodik nicht geeignet, eindeutige Aussagen zu treffen. Daher müssen zur Untersuchung dieses Vorganges alternative Methoden entwickelt und optimiert werden.
Bei der vorliegenden Arbeit handelt es sich um eine reine in vitro Studie. Dennoch könnten diese Ergebnisse Hinweise auf das Verhalten von hMSC unter Stimulation mit osteogenen und endothelialen Wachstumsfaktoren in vivo im Tierversuch oder im Menschen liefern.
Allerdings wird es bei der Übertragung auf eine kombiniertes in vitro- in vivo Vorgehen hinauslaufen, da das ungerichtete Wachstum von Gewebsformationen eine Hürde für in vivo Studien darstellt.
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 x 10(-8), HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 x 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 x 10(-8), HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2 x 10(-4)). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%-50% compared to 81%-100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.
Background and aims:
Small fiber neuropathy (SFN) is increasingly suspected in patients with pain of uncertain origin, and making the diagnosis remains a challenge lacking a diagnostic gold standard.
Methods:
In this case–control study, we prospectively recruited 86 patients with a medical history and clinical phenotype suggestive of SFN. Patients underwent neurological examination, quantitative sensory testing (QST), and distal and proximal skin punch biopsy, and were tested for pain-associated gene loci. Fifty-five of these patients additionally underwent pain-related evoked potentials (PREP), corneal confocal microscopy (CCM), and a quantitative sudomotor axon reflex test (QSART).
Results:
Abnormal distal intraepidermal nerve fiber density (IENFD) (60/86, 70%) and neurological examination (53/86, 62%) most frequently reflected small fiber disease. Adding CCM and/or PREP further increased the number of patients with small fiber impairment to 47/55 (85%). Genetic testing revealed potentially pathogenic gene variants in 14/86 (16%) index patients. QST, QSART, and proximal IENFD were of lower impact.
Conclusion:
We propose to diagnose SFN primarily based on the results of neurological examination and distal IENFD, with more detailed phenotyping in specialized centers.
Objective: To assess patterns and impact of small nerve fiber dysfunction and pathology in patients with fibromyalgia syndrome (FMS).
Methods: One hundred seventeen women with FMS underwent neurological examination, questionnaire assessment, neurophysiology assessment, and small fiber tests: skin punch biopsy, corneal confocal microscopy, microneurography, quantitative sensory testing including C-tactile afferents, and pain-related evoked potentials. Data were compared with those of women with major depressive disorder and chronic widespread pain (MD-P) and healthy women.
Results: Intraepidermal nerve fiber density (IENFD) was reduced at different biopsy sites in 63% of FMS patients (MDP: 10%, controls: 18%; p < 0.001 for each). We found 4 patterns of skin innervation in FMS: normal, distally reduced, proximally reduced, and both distally and proximally reduced (p < 0.01 for each compared to controls). Microneurography revealed initial activity-dependent acceleration of conduction velocity upon low frequencies of stimulation in 1A fibers, besides 1B fiber spontaneous activity and mechanical sensitization in FMS patients. FMS patients had elevated warm detection thresholds (p < 0.01), impaired C-tactile afferents (p < 0.05), and reduced amplitudes (p < 0.001) of pain-related evoked potentials compared to controls. Compared to FMS patients with normal skin innervation, those with generalized IENFD reduction had higher pain intensity and impairment due to pain, higher disease burden, more stabbing pain and paresthesias, and more anxiety (p < 0.05 for each). FMS patients with generalized IENFD reduction also had lower corneal nerve fiber density (p < 0.01) and length (p < 0.05).
Interpretation: The extent of small fiber pathology is related to symptom severity in FMS. This knowledge may have implications for the diagnostic classification and treatment of patients with FMS.
In our study, we aimed at investigating corneal langerhans cells (LC) in patients with fibromyalgia syndrome (FMS) and small fiber neuropathy (SFN) as potential contributors to corneal small fiber pathology. We enrolled women with FMS (n = 134) and SFN (n = 41) who underwent neurological examination, neurophysiology, prostaglandin analysis in tear fluid, and corneal confocal microscopy (CCM). Data were compared with those of 60 age‐matched female controls. After screening for dry eye disease, corneal LC were counted and sub‐classified as dendritic (dLC) and non‐dendritic (ndLC) cells with or without nerve fiber association. We further analyzed corneal nerve fiber density (CNFD), length (CNFL), and branch density (CNBD). Neurological examination indicated deficits of small fiber function in patients with SFN. Nerve conduction studies were normal in all participants. Dry eye disease was more prevalent in FMS (17%) and SFN (28%) patients than in controls (5%). Tear fluid prostaglandin levels did not differ between FMS patients and controls. While corneal LC density in FMS and SFN patients was not different from controls, there were fewer dLC in association with nerve fibers in FMS and SFN patients than in controls (P < .01 each). Compared to controls, CNFL was lower in FMS and SFN patients (P < .05 each), CNFD was lower only in FMS patients (P < .05), and CNBD was lower only in SFN patients (P < .001). There was no difference in any CCM parameter between patients with and without dry eyes. Our data indicate changes in corneal innervation and LC distribution in FMS and SFN, potentially based on altered LC signaling.